Joseph D. Khoury

University of Nebraska Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

A single, universally used tumor classification system is critical to ensure precision in patient care, clinical trial enrollment, and advancing therapy. Since the publication of the third edition of the World Health Organization (WHO) classification in 2001, the hematology and hematopathology community has benefited from a single, widely accepted classification system. However, in 2022, 2 separate classification systems of hematologic and lymphoid neoplasms emerged, namely the fifth edition of the WHO Classification of Haematolymphoid Tumours and the International Consensus Classification. This has created confusion and has led to a global call to action to return to a single classification system. In 2024, leaders of the Society for Hematopathology (SH) and the European Association for Haematopathology (EA4HP), together with the leadership of the WHO Classification of Tumours, developed a plan to bridge the division and unite around the next edition of the WHO Classification of Haematologic and Lymphoid Tumours (WHO6). This plan entails convening a classification advancement meeting (CAM), organized by the SH and EA4HP, with broad participation by pathologists, clinicians, and geneticists to discuss and debate updates and changes to the existing classifications. Published conclusions of the CAM meeting will be available for independent consideration by the editorial board of WHO6. We are convinced that engagement with the broader community and the leveraging of global expertise to unite around WHO6 will critically benefit patients, medicine, and science.

Year:

2026

Supplementary methods. Supplementary Figure 1. Phenotyping of B-cells in non-malignant tissues. A, Quantitation of marker positivity across ten tonsil and two reactive lymph node samples (rLN). Analysis is spatially resolved between the GC and extra-GC zones. B, Spatial map of cellular coordinates based on cell segmentation of images in Figure 1B. Marker-positivity is indicated, and a total proportion of positive and negative cells is depicted as a pie chart. These maps were used to derive sub-population phenotypes depicted in Figure 1C. Scale bar is 100μm. C, Proliferation analysis (i.e., Ki67-positivity) among sub-populations in five tonsil samples. Median with interquartile range, whiskers denote 10th and 90th percentile. Supplementary figure 2. Example pseudo-colored mfIHC images for MYC, BCL2, BCL6 cases in DLBCL. Images of a range of mean fluorescent intensities are shown with equal scaling for reference. Supplementary figure 3. Global distribution of MYC, BCL2 and BCL6 sub-populations within DLBCL cohorts. Heat-maps displaying the percentage extent of individual markers and each sub-population within the DLBCL NUH, CMMC, SGH and MDA cohorts. Hierarchical k-means clustering of patients according to sub-population extent is applied. Positivity shading for single markers ranges between 0-100% positivity, whereas shading for sub-populations reflects 0-50% positivity and remains fully saturated until 100%. IPI Risk Group - International Prognostic Index Risk Group, FISH - fluorescence in situ hybridization. Supplementary figure 4. Intra-tumor heterogeneity of sub-populations. A, Correlation of sub-population extent quantification between two biopsies of the same patient for which at least two tissue microarray (TMA) biopsies are available. Correlation is shown separately for lymph node and extranodal biopsies. Spearman rho is indicated for each correlation. Axes are in exponential and equivalent in all panels. B, Sub-population percentage extent quantification across multiple TMA cores (columns) of the same patient (rows). Pie charts are ordered according to decreasing cell numbers evaluated per core. All patients from the NUH cohort with at least five cores are evaluated. A heterogenous cluster is highlighted by the red box. Supplementary figure 5. Spatial heterogeneity of sub-population interactions. A, Conceptual schematic of pair correlation function (PCF) plots depicting a clustered distribution (left, green) and a random distribution (right, grey). Representative counterpart spatial maps are above each plot. B, PCF analysis for sub-populations to investigate spatial clustering (top). Mean results for two independent cohorts (shading is cohort standard deviation). An example tissue microarray core is shown as physical distance reference for spatial analyses (bottom left). Absolute number of neighboring cells expected within a given radius (data from 3500 randomly selected cells across all images, mean with standard deviation) (bottom right). C, Actual spatial map of sub-populations of an example DLBCL case (top). Extent of all sub-populations within the sample is shown on the left. Simulated, hypothetical random distribution of cells for the same case (middle). PCF analysis for the shown sample and its matched simulated random distribution (bottom). Scale bars in B and C are 100µm. D, Mean deviations from expected neighbor abundance (Δ%) summarizing cell-cell interactions between sub-populations for the sample shown in (C). E, Sub-population interaction matrices from spatially distinct biopsies (cores in tissue microarray) for example DLBCL patients. Biopsies of stable, spatially homogenous, sub-population interaction profiles are grouped (top), whereas biopsies of a differing, heterogenous, interaction profile are grouped separately (bottom). Supplementary figure 6. Global deviations from expected spatial neighbor abundance (Δ%). Hierarchical clustering (minimum variance method) of measured Δ% for all cases in the S

Year:

2025

Supplementary table 1. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for normal tonsil tissue and reactive lymph node tissue. Supplementary table 2. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for DLBCL tissue (NUH, CMMC, SGH, MDA, BCA and UP). Supplementary table 6. Inferred percentage extents of MYC, BCL2, BCL6 and sub-population metrics in GEP cohorts. Supplementary table 11. Correlation of M+2+6- metric with gene expression in GEP cohorts. Supplementary table 12. Differential gene expression analysis of primary germinal center (GC) B-cells with M+2+ and M+2+6+ overexpression. Supplementary table 13. Differentially expressed genes between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL. Dichotomized non-parametric comparison, Wilcoxon rank sum test. Supplementary table 14. Analysis of positive enrichment of Wikipathways terms between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL by gprofiler2.

Year:

2025

TdT is occasionally expressed in large B-cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B-lymphoblastic leukaemia/lymphomas (B-ALL/LBL). We reviewed 31 cases of TdT-positive LBCL and B-ALL/LBL, and their final diagnosis included 19 diffuse large/high-grade BCL with MYC and BCL2 rearrangements (DLBCL/HGBCL- MYC / BCL2 ), 3 DLBCL-NOS, 3 HGBCL-NOS, 4 B-ALL/LBL and 2 unclassifiable cases. TdT was variably expressed in all these cases, without any clear demarcation among different groups. Loss or partial loss of CD20 expression was seen in 13/17 DLBCL/HGBCL- MYC / BCL2 , 2/3 HGBCL-NOS, 2/2 unclassified, albeit not in DLBCL-NOS. Expression of BCL6 and/or MUM1 was seen in 3/4 B-ALL/LBL and 2/2 unclassified. Next generation sequencing revealed characteristic mutations associated with follicular lymphoma and its high-grade transformation in each DLBCL/HGBCL- MYC / BCL2 , and also frequent variants in genes targeted by somatic hypermutation (SHM) in almost all DLBCL/HGBCL- MYC / BCL2 , DLBCL-NOS and HGBCL-NOS but one case. In contrast, such mutations were absent in B-ALL/LBL. There were no pathognomonic mutations in the two unclassifiable cases although one showed a moderate level of somatic mutations in its rearranged IGHV . In conclusion, mutation profiling analysis including the SHM target genes is highly valuable in differential diagnosis between TdT-positive LBCL and B-ALL/LBL.

Year:

2025

Purpose: Treatment outcomes in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remains dismal. On the basis of both extensive preclinical data and emerging clinical data, treatment with bromodomain and extra-terminal domain inhibitors (BETi) is a potential approach for patients with high-risk myeloid malignancies. Patients and Methods: We conducted a phase I trial to study the safety and efficacy of PLX51107 (BETi) and azacitidine combination therapy in patients with R/R AML and high-risk (HR) MDS and studied mechanisms of resistance to the combination therapy. Results: Thirty-seven patients with HR R/R MDS ( n = 4) and R/R AML ( n = 33) were treated. Sixteen patients (43%) had MECOM gene rearrangement and 7 other patients had TP53 mutation. Median prior number of therapies was three (range 1–9); 97% had received prior hypomethylating agent and 84% prior venetoclax. Overall response rate was 8/37 (22%): complete remission with incomplete platelet recovery ( n = 1); morphologic leukemia-free state ( n = 2); hematologic improvement ( n = 5). The most common nonhematologic toxicities were febrile neutropenia and pneumonia in 12 (32%) patients each; 6 patients (17%) had severe hyperbilirubinemia. RNA-sequencing analysis of mononuclear cells harvested on treatment (day 3) versus pretreatment showed significant changes in mRNA expressions in responders: downregulation of MYC , BCL2 , IL7R , and CDK6 and upregulation of HEXIM1 , CD93 , DCXR , and CDKN1A . Immunoblot analyses confirmed reduction in protein levels of c-Myc, CDK6, BCL2, and BCL-xL, and induction of BRD4 and HEXIM1 protein levels in responders. Conclusions: In a heavily pretreated patient cohort with R/R MDS and AML, PLX51107+ azacitidine was well-tolerated and resulted in modest clinical benefit.

Year:

2025

In recent years, technology developments and increase in knowledge have led to profound changes in the diagnostics of haematologic neoplasms, particularly myeloid neoplasms. Therefore an updated, fifth edition of the World Health Organization (WHO) classification of haematolymphoid neoplasms (WHO-HAEM5) will be issued in 2024. In this context, we present a practical guide for analysing the genetic aspects of clonal haematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic neoplasms (MDS), and acute myeloid leukaemia (AML) based on WHO-HAEM5. This guide navigates through the genetic abnormalities underlying myeloid neoplasms which are required to be detected for classification according to WHO-HAEM5 and provides diagnostic algorithms.

Year:

2024

Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3ζ creates a platform that recruits critical kinases, such as lymphocyte-specific protein tyrosine kinase (LCK) and zeta-chain-associated protein kinase 70 (ZAP70), initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy. Significance: We demonstrated that incorporation of the T-cell–centric costimulatory molecule CD28, which is normally absent in mature natural killer (NK) cells, into the chimeric antigen receptor (CAR) construct recruits key kinases including lymphocyte-specific protein tyrosine kinase and zeta-chain-associated protein kinase 70 and results in enhanced CAR-NK cell persistence and sustained antitumor cytotoxicity.

Year:

2024

Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO–treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.

Year:

2024

Collaborators (58)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Irina I Mohorianu

Professor of Machine Learning and Bioinformatics

University of Maastricht

NETHERLANDS
View details

Lewis Nasr

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gautam Borthakur

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Navin Varadarajan

Professor

University of Houston

UNITED STATES
View details

Susan Swee Shan Hue

-

SINGAPORE
View details

Siok-Bian Ng

Professor

National University of Singapore (NUS)

SINGAPORE
View details

David W. Scott

The University of British Columbia

CANADA
View details

Choon Kiat Ong

Head

National Cancer Center

SINGAPORE
View details

Elizabeth Shpall

Department Chair ad interim

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Biederstädt

Physician Scientist and Junior Group Leader

Technical University of Munich

GERMANY
View details

Francisco Vega

Professor/Chief Lymphoma Section

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Claudio Tripodo

-

ITALY
View details

Lise Mette Rahbek Gjerdrum

Københavns Universitet

DENMARK
View details

Katayoun Rezvani

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth J. Soilleux

University of Cambridge

UNITED KINGDOM
View details

Jayastu Senapati

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel James Hodson

-

UNITED KINGDOM
View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pedro Farinha

Clinical Professor

The University of British Columbia

CANADA
View details

Marina Konopleva

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Anand D. Jeyasekharan

National University of Singapore (NUS)

SINGAPORE
View details

Shaoying Li

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ye Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Soo-Yong Tan

Head/Senior Consultant

National University of Singapore (NUS)

SINGAPORE
View details

Hind Rafei

Assistant Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ming‐Qing Du

University of Cambridge

UNITED KINGDOM
View details

Beenu Thakral

Associate Professor

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

UNITED STATES
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

Jan A. Burger

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rafet Basar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Koji Sasaki

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nitin Jain

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Farhad Ravandi

Professor of Medicine, Chief Section of AML

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kapil Bhalla

-

UNITED STATES
View details

Wolfram Klapper

Kiel University

GERMANY
View details

Ewelina Madej

University of Cambridge

UNITED KINGDOM
View details

Naveen Pemmaraju

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

jinmiao chen

Associate Professor

Duke-NUS Medical School

SINGAPORE
View details

Nicholas J. Short

-

UNITED STATES
View details

Warren Fiskus

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pinaki Banerjee

Assistant Professor, Director: Adoptive Cell Therapy Platform Research

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

May Daher

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nathaniel Wilson

Assistant Professor of Hematology and Medical Oncology

Winship Cancer Institute of Emory University

UNITED STATES
View details

Yesid Alvarado Valero

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tapan M. Kadia

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elias J. Jabbour

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hyungwon Choi

Associate Professor

National University of Singapore (NUS)

SINGAPORE
View details

Courtney D. DiNardo

University of Pennsylvania

UNITED STATES
View details

Wee Joo Chng

National University of Singapore (NUS)

SINGAPORE
View details

Pei Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details

Jason J Pitt

National University of Singapore (NUS)

SINGAPORE
View details

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Naval G. Daver

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details